Merck’s Drug for Diabetes-related Eye Disease Meets Trial Goal

by Medscape • 2026/09/24 • 0 Comments

Merck said on Thursday its injectable drug for a serious eye disease affecting people with diabetes was as effective ⁠as the current standard treatment in improving visual...
Reuters Health Information

← Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema

Underrepresented physicians: Negotiation is ‘asking for fairness’ →